Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 09, 2022

SELL
$1.83 - $4.48 $361,620 - $885,279
-197,607 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$2.25 - $3.03 $81 - $109
-36 Reduced 0.02%
197,607 $512,000
Q2 2021

Jul 23, 2021

BUY
$2.72 - $4.04 $537,588 - $798,477
197,643 New
197,643 $587,000
Q1 2021

May 10, 2021

SELL
$3.62 - $6.34 $715,362 - $1.25 Million
-197,614 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$3.82 - $5.32 $26 - $37
7 Added 0.0%
197,614 $994,000
Q4 2020

Feb 12, 2021

BUY
$3.82 - $5.32 $754,858 - $1.05 Million
197,607 New
197,607 $994,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Bank Julius Baer & Co. Ltd, Zurich Portfolio

Follow Bank Julius Baer & Co. Ltd, Zurich and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.